Loading asset research
Oruka Therapeutics Inc. Common Stock
ORKANasdaq · USD · StocksQuote as of · Exchange session not verified$92.36
+0.78%
Today
ORKA
Loading 1D prices…
Market cap
$6.1B
Volume
585.3K
52w high
$115.5252w low
$14.67Company profile
Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Menlo Park, CA, United States
Employees
68
Fiscal year end
1231
CIK
907654
Session & valuation
Open$93.40
Previous close$91.65
Day high$94.29
Day low$90.48
30-day avg. volume760.5K
Outstanding shares66.2M
Diluted EPS-$1.85
Latest annual period
P/E (trailing)-49.93
P/E (forward)-32.28
Price / book5.08
Beta-0.21
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| TVTXTravere Therapeutics Inc. Common Stock | $6.2B | $490.7M | -5.21% | -$0.29 | -2.04% | Buy |
| LQDALiquidia Corporation Common Stock | $6B | $158.3M | -43.53% | -$0.80 | -1.68% | Buy |
| KNSAKiniksa Pharmaceuticals International plc Class A Ordinary Shares | $6B | $677.6M | +8.71% | $0.75 | -0.31% | Buy |
| DNTHDianthus Therapeutics Inc. Common Stock | $5.9B | $2M | -7973.33% | -$4.20 | +2.83% | Buy |
| AMRXAmneal Pharmaceuticals Inc. Class A Common Stock | $5.9B | $3B | +2.39% | $0.22 | +0.86% | Buy |